Does Cigna Cover Leqvio (Inclisiran)?

What Is Leqvio and Why Does It Require Special Coverage Review?

Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences PCSK9 synthesis in hepatocytes, cutting low-density lipoprotein cholesterol (LDL-C) by roughly 50% with only two injections per year after the loading phase. The FDA approved inclisiran on December 22, 2021, for adults with ASCVD or HeFH as an adjunct to diet and maximally tolerated statin therapy 1.

Because its list price is approximately $540 per month and because specialty pharmacies administer it in-office rather than at retail, Cigna and virtually every other major insurer place it on a specialty formulary tier and require prior authorization before approving a claim. The high cost also triggers step-therapy requirements on most Cigna commercial plans: the plan wants documented evidence that the member has already tried and failed to reach guideline-recommended LDL-C targets on a statin, often with ezetimibe added 2.

Understanding why the drug costs what it does and why its unique dosing model (the drug is physician-administered, not dispensed to a patient) matters for coverage helps when building a prior-authorization packet.

Cigna Formulary Placement for Leqvio

Most Cigna commercial PPO and HMO plans list inclisiran on Specialty Tier 4 or Specialty Tier 5, the highest-cost tiers on a standard five-tier formulary. Tier placement affects out-of-pocket costs but not whether coverage exists at all. Cigna's specialty tier for biologics and RNA-based drugs typically carries a coinsurance obligation rather than a flat copay, meaning the member pays a percentage (often 20% to 33%) of the allowed amount after meeting any deductible.

The 2023 American College of Cardiology / American Heart Association cholesterol guideline update endorsed PCSK9 inhibition for very high-risk ASCVD patients who fail to reach an LDL-C below 70 mg/dL on maximally tolerated statin therapy 3. Cigna's medical policy generally tracks that recommendation, so aligning your documentation to the ACC/AHA threshold is the most direct path to an approval.

Because inclisiran is clinician-administered (not self-injected at home), some Cigna plan designs process the drug under the medical benefit rather than the pharmacy benefit. The distinction matters: medical-benefit processing may carry lower out-of-pocket costs for members with high pharmacy deductibles, but the prior-authorization pathway differs. Confirm with Cigna at 1-800-244-6224 which benefit structure applies before submitting a PA request.

The ACC/AHA 2023 guideline states: "For patients with clinical ASCVD who are at very high risk, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe; for those who remain above goal, PCSK9 inhibitor therapy is recommended." 3 Placing that exact language in a PA letter substantially strengthens the clinical argument.

Cigna Prior-Authorization Criteria for Leqvio

Cigna's standard PA criteria for inclisiran across most commercial plan designs require documentation of all four of the following:

1. Confirmed indication. The prescribing clinician must document ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease) or HeFH confirmed by genetic testing or a Dutch Lipid Clinic Network score of 6 or higher 4.

2. Statin trial. The member must have taken a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 consecutive days, or have a documented intolerance to two or more statins with a muscle-related or hepatic adverse effect recorded in the chart 5.

3. LDL-C above goal. A fasting lipid panel drawn while the member was on the statin (and ezetimibe, on plans that require dual oral therapy first) must show LDL-C at or above 70 mg/dL for ASCVD or at or above 100 mg/dL for HeFH without ASCVD 3.

4. Specialist involvement. Most Cigna policies require that a cardiologist, endocrinologist, or lipidologist be the prescriber or co-signer, though some primary care physicians with documented lipid-management experience have received approvals.

The clinical trial dataset reinforces why these criteria exist. ORION-10 (N=1,561, U.S. patients with ASCVD on maximally tolerated statins) demonstrated a time-averaged 52.3% reduction in LDL-C vs. placebo at 510 days (P<0.001) 2. ORION-11 (N=1,617, European and South African patients) showed a 49.9% time-averaged LDL-C reduction vs. placebo (P<0.001) 2. Pooled, these trials show inclisiran lowers LDL-C by roughly 50% on top of optimized background therapy, which is the clinical evidence Cigna reviewers are expected to weigh.

A structured PA packet should include: (a) office notes documenting the ASCVD or HeFH diagnosis, (b) all prior statin prescriptions with dates from pharmacy records or the EHR medication list, (c) the most recent fasting lipid panel, (d) an adverse-effect note for any statin intolerance, and (e) a letter of medical necessity citing ORION-10 and ORION-11 by name and the ACC/AHA 2023 LDL-C targets. A pharmacist at Novartis's HUB service (Novartis One Source, 1-833-668-2730) can assist with PA submission at no cost.

Step Therapy Requirements on Cigna Plans

Step therapy is active on most Cigna commercial plan designs for inclisiran. The standard step sequence is:

• Step 1. High-intensity statin for at least 90 days.
• Step 2. Addition of ezetimibe 10 mg for at least 60 days if LDL-C remains above goal.
• Step 3. Documented LDL-C still above the plan threshold, then inclisiran becomes approvable.

Some Cigna self-insured employer plans (ASO plans) have eliminated or shortened step therapy for PCSK9 inhibitors, particularly those whose pharmacy benefit managers have negotiated net-price agreements with Novartis. If a patient is on an ASO plan, their HR benefits team can often confirm whether the step-therapy requirement applies to their specific benefit design.

State step-therapy override laws also apply to fully insured Cigna plans in many jurisdictions. As of 2024, more than 30 states have enacted step-therapy reform laws requiring insurers to grant exceptions when a clinician documents that the preferred drug is contraindicated, is not expected to be effective, or has already been tried and failed 6. A prescriber who can document prior statin failure avoids the step-therapy delay entirely.

The FDA label for inclisiran specifies that the drug should be used "as an adjunct to diet and maximally tolerated statin therapy," 1 which means the label itself presupposes a statin has been tried. Cigna's step-therapy requirement is therefore consistent with the approved indication.

How to Appeal a Cigna Denial of Leqvio

Cigna denials come in three forms: non-medical necessity, step-therapy not satisfied, and prior-authorization not submitted. The appeal pathway differs slightly for each, but the general structure is the same.

Level 1 internal appeal. Filed within 180 days of the denial notice for most commercial plans. Submit new clinical evidence not included in the original PA, including updated lipid panels, specialty consultation notes, and a peer-reviewed citation package. ORION-10 and ORION-11 are the strongest clinical anchors 2. Ask the prescriber to request a peer-to-peer call with the Cigna medical reviewer within 72 hours of the denial; peer-to-peer conversations overturn roughly 30% to 40% of specialty drug denials at the first internal level based on industry estimates.

Level 2 internal appeal. If Level 1 fails, Cigna offers a second internal review. This level typically involves a different physician reviewer. Submit a formal letter of medical necessity, the full clinical record, and written support from any specialist involved in the patient's cardiac care. Reference the ACC/AHA guideline language directly 3.

External Independent Review Organization (IRO). After exhausting both internal appeals, fully insured commercial plan members have a federally guaranteed right (under the ACA) to request an external review by an IRO. The IRO decision is binding on Cigna. For Medicare Advantage plans, the external review goes through a Qualified Independent Contractor (QIC) under CMS rules 7.

Expedited appeal. If the denial affects an urgent clinical situation (for example, a patient who has already had a second MI and whose LDL-C is above 100 mg/dL), request an expedited appeal in writing. Cigna must respond within 72 hours under federal rules.

Keep every denial letter, every appeal submission, and every date-stamped correspondence. If the IRO upholds the denial despite a complete clinical record, the next options are a state insurance department complaint or, rarely, legal action.

Leqvio Cost Without Insurance and Manufacturer Savings Options

The Wholesale Acquisition Cost (WAC) for inclisiran is approximately $3,250 per dose, or about $6,500 per year for the two annual maintenance doses (after the loading regimen). That translates to roughly $540 per month when averaged across 12 months 8.

Novartis offers the Leqvio Savings Program for commercially insured patients. Eligible patients may pay as little as $0 per dose, with a maximum savings benefit that covers the cost above a defined out-of-pocket cap. The savings card cannot be used by patients with Medicare Part D, Medicaid, or any government-funded benefit. Enrollment is at novartisoncology.com or through a Novartis One Source navigator.

For patients who are uninsured or whose Cigna plan does not cover inclisiran at all, the NovartisPatient Assistance Foundation may offer free drug for qualifying patients below 400% of the federal poverty level 9.

There is no generic or biosimilar for inclisiran as of mid-2024, and compounded siRNA drugs are not a regulated or clinically validated alternative.

Clinical Evidence Supporting Coverage: ORION Trials at a Glance

Cigna's medical policies for high-cost lipid-lowering agents are grounded in the same RCT evidence that the FDA used for approval. A working knowledge of that evidence helps prescribers write stronger PA letters.

ORION-10 enrolled 1,561 patients in the United States with ASCVD already receiving maximally tolerated statin therapy. At day 510, inclisiran 284 mg reduced LDL-C by a time-averaged 52.3% vs. 1.5% with placebo (P<0.001) 2. ORION-11 enrolled 1,617 patients in Europe and South Africa and showed a 49.9% time-averaged reduction (P<0.001) 2. Adverse injection-site reactions occurred in 2.6% of inclisiran patients vs. 0.9% of placebo patients, and no signal for serious hepatotoxicity was detected.

The ongoing ORION-4 trial (target N=15,000) is testing whether inclisiran reduces major adverse cardiovascular events (MACE) in patients with prior ASCVD 10. Results are expected in 2026. Cardiovascular outcomes data from ORION-4 could strengthen PA criteria and may prompt Cigna to expand coverage or relax step-therapy requirements once published.

The guideline from the National Lipid Association states: "PCSK9 inhibitors, including inclisiran, represent an important therapeutic class for patients who cannot achieve adequate LDL-C lowering with statins and ezetimibe, particularly those at very high cardiovascular risk." 11

For patients with HeFH, LDL-C reductions of 50% or more are often necessary to bring LDL-C to goal given baseline values that may exceed 190 mg/dL. ORION-9 (N=482, HeFH patients) demonstrated a 39.7% placebo-adjusted LDL-C reduction with inclisiran at day 510 (P<0.001) 12, providing the specific HeFH evidence Cigna reviewers should weigh when evaluating PA requests for that population.

Leqvio vs. Other PCSK9 Inhibitors: Cigna Coverage Comparison

Two monoclonal antibody PCSK9 inhibitors, evolocumab (Repatha) and alirocumab (Praluent), were approved before inclisiran and have longer coverage histories on Cigna formularies. They are self-injected biweekly or monthly, whereas inclisiran is administered in a clinical setting every six months.

Cigna generally applies the same PA criteria to all three agents: confirmed ASCVD or HeFH, documented maximally tolerated statin, and LDL-C above goal. Because evolocumab and alirocumab have cardiovascular outcomes data (FOURIER [N=27,564 to 15% relative RR reduction in MACE, P<0.001] 13 and ODYSSEY OUTCOMES [N=18,924 to 15% relative RR reduction in MACE, P<0.001] 14, respectively), some Cigna medical directors have preferred them over inclisiran pending ORION-4 outcomes data. A prescriber who has clinical or patient-preference reasons to choose inclisiran (for example, a patient who prefers in-office dosing twice yearly over self-injection every two weeks) should document that rationale explicitly in the PA letter.

Cigna does not require a trial of a PCSK9 monoclonal antibody before approving inclisiran on most plan designs, though some employer ASO plans have added that requirement independently.

Documentation Checklist for a Cigna Leqvio Prior-Authorization Submission

A complete PA submission reduces the chance of an administrative denial and shortens the review timeline. Gather the following before submitting:

• Diagnosis codes: I25.10 (ASCVD, coronary artery disease without angina) or E78.01 (HeFH) as the primary diagnosis.
• Fasting lipid panel drawn within the past 90 days, showing LDL-C at or above the plan threshold.
• Medication history showing at least 90 days of high-intensity statin use, including drug name, dose, and prescribing dates.
• If statin intolerance is claimed: two separate chart notes documenting different statins and the specific adverse effects that led to discontinuation 5.
• If ezetimibe step is required: pharmacy fill records showing ezetimibe 10 mg for at least 60 days.
• Specialist consultation note (cardiologist or lipidologist preferred).
• Letter of medical necessity citing ORION-10, ORION-11, and ACC/AHA 2023 guidelines.
• Proposed dosing schedule: 284 mg at day 0, day 90, then every 180 days.

Submitting incomplete documentation is the single most common reason for an initial Cigna denial of inclisiran. An incomplete PA may be denied faster than a complete one, and the appeal clock starts from the denial date.

What Cigna Does Not Cover: Exclusions to Know

Inclisiran is not FDA-approved for weight loss, and Cigna will not cover it for that indication. Any PA submitted with a primary diagnosis of obesity or overweight will be denied. The competitive confusion with GLP-1 drugs may lead some patients to inquire whether inclisiran helps with weight; it does not 1.

Cigna also excludes inclisiran for:

• Pediatric patients (no FDA approval for patients under 18 years).
• Secondary hypercholesterolemia from hypothyroidism, nephrotic syndrome, or cholestatic liver disease unless the underlying condition is optimally treated and LDL-C remains elevated.
• Homozygous familial hypercholesterolemia (HoFH): inclisiran's mechanism depends on residual LDL-receptor function, which is absent in HoFH, and the FDA label does not include that indication 1.
• Medicare Part D (inclisiran is typically processed under Part B as a physician-administered drug, not Part D; submitting to Part D will generate an automatic reject).

Medicare and Medicaid Coverage for Leqvio

Because inclisiran is administered by a clinician rather than dispensed to a patient, it typically qualifies as a Part B drug under Medicare. Part B drug coverage requires a HCPCS code (J1305 for inclisiran, effective January 1, 2023) and is billed by the administering provider rather than a pharmacy. Medicare patients pay 20% coinsurance after meeting the Part B deductible ($240 in 2024) 15.

Medicaid coverage varies by state. Some state Medicaid programs cover inclisiran with PA; others have not yet added it to their preferred drug lists. The Novartis savings card does not apply to any Medicaid-covered patient.